Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Multi-centre, Phase II Study of Oral Lapatinib in Combination With Paclitaxel as First-line Treatment for ErbB2-amplified Metastatic Breast Cancer Patients

NCT00356811 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00356811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00356811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Multi-centre, Phase II Study of Oral Lapatinib in Combination With Paclitaxel as First-line Treatment for ErbB2-amplified Metastatic Breast Cancer Patients
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
December 31, 2013
Enrollment
57 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast